Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. director R John Fletcher received a grant of 12,820 restricted stock units as equity compensation. Each unit represents a contingent right to one share of CLPT common stock. The units vest on the earlier of the first anniversary of the grant date or the day immediately before the company’s 2027 annual meeting of stockholders. Following this award, Fletcher holds 12,820 RSUs directly.
JOHNSON B KRISTINE reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Kristine B. Johnson received a grant of restricted stock units. She was awarded 12,820 restricted stock units, each representing a contingent right to receive one share of ClearPoint Neuro common stock. These units vest on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual meeting of stockholders. After this award, she holds 12,820 RSUs directly related to ClearPoint Neuro common stock.
ClearPoint Neuro director Matthew B. Klein settled a restricted stock unit award into common shares. On the May 19, 2026 vesting date, 12,417 restricted stock units converted into an equal number of ClearPoint Neuro common shares at no cash exercise price. These RSUs were originally granted on May 22, 2025 and were scheduled to vest on the earlier of the first anniversary of the grant or the day immediately before the company’s 2026 annual stockholders’ meeting. Following this routine equity compensation event, Klein directly holds 62,935 shares of ClearPoint Neuro common stock.
ClearPoint Neuro director Lynnette C. Fallon reported routine equity compensation activity. She exercised 12,417 restricted stock units into common stock at a conversion price of $0.00 per share, then sold 5,091 shares at a weighted average price of $11.14.
The footnotes state the sale was made under a pre-arranged Rule 10b5-1 trading plan to cover tax liabilities from the RSU vesting, rather than a discretionary trade. After these transactions, she directly holds 48,227 shares of ClearPoint Neuro common stock.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director R. John Fletcher increased his direct holdings through routine equity compensation. On May 19, 2026, 12,417 restricted stock units vested and were settled into 12,417 shares of common stock, with no open-market buying or selling involved.
These RSUs were originally granted on May 22, 2025 and vested on their scheduled date, tied to the first anniversary or the day before the 2026 annual stockholder meeting. Following the settlement, Fletcher directly holds 130,349 shares of ClearPoint Neuro common stock.
ClearPoint Neuro, Inc. held its annual stockholder meeting on May 20, 2026. Stockholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan, which had previously been adopted by the board subject to stockholder approval, and the full text was filed as an exhibit.
All director nominees were elected to serve until the 2027 annual meeting, each receiving over 9.6 million votes in favor, with additional broker non-votes recorded. Stockholders also ratified Cherry Bekaert LLP as independent auditor for the fiscal year ending December 31, 2026, and gave advisory approval to executive compensation.
Following the meeting, the board set new committee memberships for the audit, compensation, and corporate governance and nominating committees, determining that all members are independent under Nasdaq rules. The board also confirmed R. John Fletcher as Chairman of the Board.
ClearPoint Neuro director Timothy T. Richards exercised 12,417 restricted stock units into 12,417 shares of common stock. The RSUs were granted on May 22, 2025 and vested on their scheduled vesting date, converting into common shares at no cash exercise price.
Following this settlement of equity compensation, Richards directly owns 92,613 shares of ClearPoint Neuro common stock. The filing does not show any open-market purchases or sales, only the vesting and share issuance related to previously granted RSUs.
ClearPoint Neuro director Kristine B. Johnson exercised and settled 12,417 restricted stock units into an equal number of common shares on May 19, 2026. These RSUs were granted on May 22, 2025 and vested on their scheduled vesting date. After the settlement, she directly holds 71,116 shares of ClearPoint Neuro common stock.
ClearPoint Neuro director Pascal E. R. Girin settled a restricted stock unit award into common shares. On May 19, 2026, he exercised 12,417 restricted stock units, receiving 12,417 shares of ClearPoint Neuro, Inc. common stock at no cash exercise price. After this settlement, he directly holds 110,623 common shares. The RSUs were originally granted on May 22, 2025 and vested on their scheduled vesting date tied to the earlier of the first anniversary of grant or the day before the company’s 2026 annual meeting of stockholders.
ClearPoint Neuro director Linda M. Liau acquired 12,417 shares of common stock through settlement of restricted stock units. These RSUs were granted on May 22, 2025 and vested on their scheduled date, converting into the same number of common shares. After this compensation-related transaction, she holds 64,801 shares of ClearPoint Neuro common stock directly. No open-market buys or sells were reported in this filing.